ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
세계의 심낭염 치료제 시장 규모는 최근 현저한 성장을 이루고 있습니다. 2024년 30억 2,000만 달러에서 2025년에는 33억 1,000만 달러로, CAGR은 9.4%로 확대가 전망되고 있습니다. 과거의 성장은 바이러스 감염 증가, 심낭염의 증상에 대한 인식 증가, 조기 진단 기법의 보급 확대, 건강 관리 지출 증가 및 제 1 선택 치료제의 사용 증가에 기인한다고 생각됩니다.
심낭염 치료제 시장 규모는 향후 수년간 강력한 성장이 예상됩니다. 2029년까지 46억 8,000만 달러에 달하고, CAGR은 9.1%가 될 전망입니다. 예측기간 동안의 성장요인으로는 맞춤형 의료에 대한 주목 증가, 자가면역질환 증가 경향, 개발도상 지역에서의 헬스케어 접근 확대, 의료 인프라에 대한 투자 증가, 노인 인구 증가 등을 들 수 있습니다. 예측기간의 주요 동향으로는 심낭염 치료용 생물학적 제제의 개발 진전, 연구 개발 활동에 대한 투자, 항염증제 제제의 혁신, 표적 요법의 개발, 임상시험 설계의 진보 등이 포함됩니다.
자가면역 질환의 유병률 증가는 향후 심낭염 치료제 시장의 성장을 가속할 것으로 예측됩니다. 자가면역 질환은 면역계가 실수로 자신의 건강한 세포와 조직을 공격하여 발생합니다. 이 유병률 증가는 주로 면역조절을 방해하여 염증이나 조직 손상을 일으키는 환경 및 생활양식의 변화에 의해 촉진되고 있습니다. 심낭염 치료제는 자가면역 활동에 의한 심낭염 관리에 중요한 역할을 합니다. 이러한 약물은 염증 완화, 증상 완화, 재발성 심낭염 및 심낭 저장 등의 합병증 예방에 기여합니다. 예를 들어 2023년 9월, 염증성 장질환(IBD) 임상연구센터에 따르면 캐나다의 IBD 유병률은 10만명당 825명, 환자수는 32만명 이상으로 증가했습니다. 유병률은 연간 2.44% 증가할 것으로 예상되며, 2035년까지 캐나다 인구의 1.1%(약 47만 명)가 IBD로 진단될 것으로 예측됩니다. IBD와 같은 자가면역 질환이 심낭염을 유발할 수 있기 때문에 이러한 질병 증가는 효과적인 심낭염 치료제에 대한 수요를 촉진하고 있습니다.
맞춤형 의료에 대한 수요 증가는 심낭염 치료제 시장의 성장을 더욱 가속화할 것으로 예측됩니다. 맞춤형 의료는 개인의 유전적, 행동적, 환경적 특성에 따라 질병 예방 및 치료 전략을 맞춤화하는 것입니다. 이 접근법은 의료 정밀화 요구 증가에 부응하고 효과를 향상시키면서 부작용을 줄인 치료법을 설계할 수 있습니다. 심낭염의 맥락에서 개인화된 의료는 환자의 고유한 유전적 및 면역학적 프로파일을 고려한 표적 요법의 개발을 지원하고, 염증의 보다 효과적인 제어와 장기적인 예후의 개선으로 이어집니다. 예를 들어, 2024년 2월에 미국 Personalized Medicine Coalition이 보고한 바에 따르면, 미국 식품의약국(FDA)은 2023년에 희소질환용 맞춤형 치료 16건을 승인하고, 이는 2022년 6건에서 크게 증가한 수치입니다. 이러한 개인화된 치료 접근법에 대한 관심 증가는 첨단 심낭염 치료제 수요를 견인하는 정밀의료의 역할 확대를 뒷받침하고 있습니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계의 심낭염 치료제 시장 : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
최종 이용 산업의 분석
세계의 심낭염 치료제 시장 : 성장률 분석
세계의 심낭염 치료제 시장 실적 : 규모와 성장, 2019-2024년
세계의 심낭염 치료제 시장 예측 : 규모와 성장, 2024-2029년, 2034F
세계의 심낭염 치료제 : 총 시장 규모(TAM)
제6장 시장 세분화
세계의 심낭염 치료제 시장 : 약제 클래스별, 분석과 예측, 2019-2024년, 2024-2029F, 2034F
비스테로이드성 항염증제(NSAIDs)
콜히친
코르티코스테로이드
기타 약품 클래스
세계의 심낭염 치료제 시장 : 투여 경로별, 분석과 예측, 2019-2024년, 2024-2029F, 2034F
경구
정맥내 투여
근육내 투여
국소
세계의 심낭염 치료제 시장 : 유통 채널별, 분석과 예측, 2019-2024년, 2024-2029F, 2034F
병원 약국
소매 약국
온라인 약국
기타 유통 채널
세계의 심낭염 치료제 시장 : 치료 용도별, 분석과 예측, 2019-2024년, 2024-2029F, 2034F
급성 심낭염 치료
재발성 심낭염 관리
심장 수술 후
심낭 삼출 관리
세계의 심낭염 치료제 시장 : 최종 사용자별, 분석과 예측, 2019-2024년, 2024-2029F, 2034F
병원
재택치료
전문 클리닉
기타 최종 사용자
세계의 심낭염 치료제 시장 : 비스테로이드성 항염증제 유형별, 분석과 예측, 2019-2024년, 2024-2029F, 2034F
이부프로펜
아스피린
인도메타신
나프록센
디클로페낙
세계의 심낭염 치료제 시장 : 콜히친 유형별, 분석과 예측, 2019-2024년, 2024-2029F, 2034F
경구 콜히친
정맥 콜히친
세계의 심낭염 치료제 시장 : 코르티코스테로이드 유형별, 분석과 예측, 2019-2024년, 2024-2029F, 2034F
프레드니손
메틸프레드니솔론
하이드로코르티손
덱사메타손
세계의 심낭염 치료제 시장 : 기타 약제 클래스, 유형별, 분석과 예측, 2019-2024년, 2024-2029F, 2034F
면역억제제
생물학적 제형
진통제
항생제
제7장 지역별/국가별 분석
세계의 심낭염 치료제 시장 : 지역별, 분석과 예측, 2019-2024년, 2024-2029F, 2034F
세계의 심낭염 치료제 시장 : 국가별, 분석과 예측, 2019-2024년, 2024-2029F, 2034F
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 프로파일
심낭염 치료제 시장 : 경쟁 구도
심낭염 치료제 시장 : 기업 프로파일
Merck & Co. Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
Pfizer Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
Bayer AG : 개요, 제품 및 서비스, 전략 및 재무 분석
Novartis AG : 개요, 제품 및 서비스, 전략 및 재무 분석
Bristol-Myers Squibb Company : 개요, 제품 및 서비스, 전략 및 재무 분석
제31장 기타 주요 기업 및 혁신 기업
Takeda Pharmaceutical Company Limited
Teva Pharmaceutical Industries Ltd.
Sun Pharmaceutical Industries Ltd.
Aurobindo Pharma Limited
Hikma Pharmaceuticals USA Inc.
Zydus Lifesciences Limited
Kiniksa Pharmaceuticals
Camber Pharmaceuticals Inc.
Scilex Holding Company
Solara Active Pharma Sciences
Alkaloids Bioactives Pvt. Ltd.
Alchem International Pvt. Ltd.
Sarv Biolabs Pvt. Ltd.
Midas Pharma GmbH
AdvaCare Pharma
제32장 세계 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병(M&A)
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 부문, 전략
심낭염 치료제 시장(2029년) : 새로운 기회를 제공하는 국가
심낭염 치료제 시장(2029년) : 새로운 기회를 제공하는 부문
심낭염 치료제 시장(2029년) : 성장 전략
시장 동향에 기초한 전략
경쟁 전략
제36장 부록
JHS
영문 목차
영문목차
Pericarditis drugs are medications designed to manage inflammation and pain affecting the pericardium, the protective membrane surrounding the heart. They work by controlling inflammatory processes and relieving discomfort, thereby supporting normal heart function and preventing complications. These medications are prescribed and monitored by healthcare professionals to ensure effective treatment and minimize potential side effects.
The main drug classes in pericarditis drugs include nonsteroidal anti-inflammatory drugs (NSAIDs), colchicine, corticosteroids, and others. Nonsteroidal anti-inflammatory drugs (NSAIDs) are used to reduce inflammation, relieve pain, and lower fever in pericarditis by inhibiting cyclooxygenase enzymes responsible for prostaglandin synthesis. The routes of administration include oral, intravenous, intramuscular, and topical, and they are distributed through several channels such as hospital pharmacies, retail pharmacies, online pharmacies, and others. These drugs are used for therapeutic applications such as acute pericarditis treatment, recurrent pericarditis management, post-cardiac surgery, and pericardial effusion management, and are utilized by end users such as hospitals, homecare, specialty clinics, and others.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.
The pericarditis drugs market research report is one of a series of new reports from The Business Research Company that provides pericarditis drugs market statistics, including pericarditis drugs industry global market size, regional shares, competitors with a pericarditis drugs market share, detailed pericarditis drugs market segments, market trends and opportunities, and any further data you may need to thrive in the pericarditis drugs industry. This pericarditis drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The pericarditis drugs market size has grown strongly in recent years. It will grow from $3.02 billion in 2024 to $3.31 billion in 2025 at a compound annual growth rate (CAGR) of 9.4%. The growth during the historic period can be attributed to the increasing prevalence of viral infections, the rising awareness about pericarditis symptoms, the growing adoption of early diagnosis practices, the rising healthcare spending, and the increasing use of first-line treatment drugs.
The pericarditis drugs market size is expected to see strong growth in the next few years. It will grow to $4.68 billion in 2029 at a compound annual growth rate (CAGR) of 9.1%. The growth during the forecast period can be attributed to the increasing focus on personalized medicine, the rising prevalence of autoimmune diseases, the expanding healthcare access in developing regions, the growing investment in healthcare infrastructure, and the rising geriatric population. Key trends in the forecast period include developments in biologics for pericarditis treatment, investment in research and development activities, innovation in anti-inflammatory drug formulations, development of targeted therapies, and advancements in clinical trial designs.
The increasing prevalence of autoimmune diseases is expected to propel the growth of the pericarditis drugs market going forward. Autoimmune diseases occur when the immune system mistakenly attacks the body's own healthy cells and tissues. This growing prevalence is largely driven by environmental and lifestyle changes that disrupt immune regulation, leading to inflammation and tissue damage. Pericarditis drugs play a critical role in managing inflammation of the pericardium caused by autoimmune activity. These medications help reduce inflammation, alleviate symptoms, and prevent complications such as recurrent pericarditis and pericardial effusion. For instance, in September 2023, according to the Inflammatory Bowel Disease (IBD) Clinical and Research Centre, Canada recorded a prevalence of 825 per 100,000 for IBD, affecting over 320,000 individuals. The prevalence is projected to rise by 2.44% annually, with 1.1% of the Canadian population (approximately 470,000 people) expected to live with IBD by 2035. Since autoimmune conditions such as IBD can trigger pericarditis, the increasing incidence of these diseases is driving the demand for effective pericarditis drug therapies.
The rising demand for personalized medicine is expected to further accelerate the growth of the pericarditis drugs market. Personalized medicine tailors disease prevention and treatment strategies based on an individual's genetic, behavioral, and environmental characteristics. This approach enables the design of therapies with improved efficacy and reduced side effects, aligning with the growing need for precision in medical care. In the context of pericarditis, personalized medicine supports the development of targeted therapies that account for a patient's unique genetic and immunological profile, leading to more effective control of inflammation and better long-term outcomes. For example, in February 2024, the Personalized Medicine Coalition (USA) reported that the U.S. Food and Drug Administration (FDA) approved 16 personalized therapies for rare diseases in 2023, up significantly from six approvals in 2022. This increasing focus on individualized treatment approaches underscores the expanding role of precision medicine in driving demand for advanced pericarditis therapeutics.
Primary companies operating in the pericarditis drugs market are focusing on the development of innovative oral therapies to improve treatment accessibility and patient compliance while reducing recurrence rates. Oral anti-inflammatory therapies are designed as small molecule formulations that modulate key inflammatory pathways through systemic, non-injectable administration. For instance, in April 2025, Cardiol Therapeutics Inc., a Canada-based clinical stage life sciences company specializing in anti-inflammatory and anti-fibrotic therapies for cardiovascular diseases, initiated a Phase III clinical trial for CardiolRx. This investigational oral therapy targets inflammasome pathway activation, a central mechanism underlying inflammation and fibrosis in pericarditis. The development of such oral, non-immunosuppressive treatments represents a significant advancement in expanding therapeutic options for patients with recurrent pericarditis, improving convenience, and enhancing long-term disease management outcomes.
Major companies operating in the pericarditis drugs market are Merck & Co. Inc., Pfizer Inc., Bayer AG, Novartis AG, Bristol-Myers Squibb Company, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Hikma Pharmaceuticals USA Inc., Zydus Lifesciences Limited, Kiniksa Pharmaceuticals, Camber Pharmaceuticals Inc., Scilex Holding Company, Solara Active Pharma Sciences, Alkaloids Bioactives Pvt. Ltd., Alchem International Pvt. Ltd., Sarv Biolabs Pvt. Ltd., Midas Pharma GmbH, AdvaCare Pharma, Actavis GmbH, Enomark LLC, Honour Lab Limited.
North America was the largest region in the pericarditis drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in pericarditis drugs report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the pericarditis drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The pericarditis drugs market consists of sales of antitubercular drugs, receptor antagonists, rilonacept, antibiotics or antifungals. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Pericarditis Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on pericarditis drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for pericarditis drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The pericarditis drugs market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Drug Class: Nonsteroidal Anti-Inflammatory Drugs (NSAIDs); Colchicine; Corticosteroids; Other Drug Class
2) By Route Of Administration: Oral; Intravenous; Intramuscular; Topical
3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies; Other Distribution Channels
3. Pericarditis Drugs Market Trends And Strategies
4. Pericarditis Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
4.1. Supply Chain Impact from Tariff War & Trade Protectionism
5. Global Pericarditis Drugs Growth Analysis And Strategic Analysis Framework
5.1. Global Pericarditis Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Pericarditis Drugs Market Growth Rate Analysis
5.4. Global Pericarditis Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Pericarditis Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Pericarditis Drugs Total Addressable Market (TAM)
6. Pericarditis Drugs Market Segmentation
6.1. Global Pericarditis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
Colchicine
Corticosteroids
Other Drug Class
6.2. Global Pericarditis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Oral
Intravenous
Intramuscular
Topical
6.3. Global Pericarditis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Other Distribution Channels
6.4. Global Pericarditis Drugs Market, Segmentation By Therapeutic Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Acute Pericarditis Treatment
Recurrent Pericarditis Management
Post-Cardiac Surgery
Pericardial Effusion Management
6.5. Global Pericarditis Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Homecare
Specialty Clinics
Other End Users
6.6. Global Pericarditis Drugs Market, Sub-Segmentation Of Nonsteroidal Anti-Inflammatory Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Ibuprofen
Aspirin
Indomethacin
Naproxen
Diclofenac
6.7. Global Pericarditis Drugs Market, Sub-Segmentation Of Colchicine, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Oral Colchicine
Intravenous Colchicine
6.8. Global Pericarditis Drugs Market, Sub-Segmentation Of Corticosteroids, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Prednisone
Methylprednisolone
Hydrocortisone
Dexamethasone
6.9. Global Pericarditis Drugs Market, Sub-Segmentation Of Other Drug Class, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Immunosuppressive Agents
Biologic Agents
Analgesics
Antibiotics
7. Pericarditis Drugs Market Regional And Country Analysis
7.1. Global Pericarditis Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Pericarditis Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Pericarditis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Pericarditis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Pericarditis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Pericarditis Drugs Market
9.1. China Pericarditis Drugs Market Overview
9.2. China Pericarditis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Pericarditis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Pericarditis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Pericarditis Drugs Market
10.1. India Pericarditis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Pericarditis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Pericarditis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Pericarditis Drugs Market
11.1. Japan Pericarditis Drugs Market Overview
11.2. Japan Pericarditis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Pericarditis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Pericarditis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Pericarditis Drugs Market
12.1. Australia Pericarditis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Pericarditis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Pericarditis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Pericarditis Drugs Market
13.1. Indonesia Pericarditis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Pericarditis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Pericarditis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Pericarditis Drugs Market
14.1. South Korea Pericarditis Drugs Market Overview
14.2. South Korea Pericarditis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Pericarditis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Pericarditis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Pericarditis Drugs Market
15.1. Western Europe Pericarditis Drugs Market Overview
15.2. Western Europe Pericarditis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Pericarditis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Pericarditis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Pericarditis Drugs Market
16.1. UK Pericarditis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Pericarditis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Pericarditis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Pericarditis Drugs Market
17.1. Germany Pericarditis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Pericarditis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Pericarditis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Pericarditis Drugs Market
18.1. France Pericarditis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Pericarditis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Pericarditis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Pericarditis Drugs Market
19.1. Italy Pericarditis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Pericarditis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Pericarditis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Pericarditis Drugs Market
20.1. Spain Pericarditis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Pericarditis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Pericarditis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Pericarditis Drugs Market
21.1. Eastern Europe Pericarditis Drugs Market Overview
21.2. Eastern Europe Pericarditis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Pericarditis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Pericarditis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Pericarditis Drugs Market
22.1. Russia Pericarditis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Pericarditis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Pericarditis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Pericarditis Drugs Market
23.1. North America Pericarditis Drugs Market Overview
23.2. North America Pericarditis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Pericarditis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Pericarditis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Pericarditis Drugs Market
24.1. USA Pericarditis Drugs Market Overview
24.2. USA Pericarditis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Pericarditis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Pericarditis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Pericarditis Drugs Market
25.1. Canada Pericarditis Drugs Market Overview
25.2. Canada Pericarditis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Pericarditis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Pericarditis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Pericarditis Drugs Market
26.1. South America Pericarditis Drugs Market Overview
26.2. South America Pericarditis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Pericarditis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Pericarditis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Pericarditis Drugs Market
27.1. Brazil Pericarditis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Pericarditis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Pericarditis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Pericarditis Drugs Market
28.1. Middle East Pericarditis Drugs Market Overview
28.2. Middle East Pericarditis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Pericarditis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Pericarditis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Pericarditis Drugs Market
29.1. Africa Pericarditis Drugs Market Overview
29.2. Africa Pericarditis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Pericarditis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Pericarditis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Pericarditis Drugs Market Competitive Landscape And Company Profiles
